GSK Updates Market on Share Capital and Voting Rights
Bird Flu Vaccine Faces Hurdles Without Better Data, Critics Say
GlaxoSmithKline (GSK) Gets a Hold From Goldman Sachs
GSK Settles Zantac Litigation in Illinois, US
Alnylam, Lilly, AstraZeneca Among Best Performing Pharmas, Biotechs in Q2
Rising Drug Costs Force a Third of Americans to Leave Prescriptions Unfilled: Report
GSK Reaches Confidential Settlement in Illinois Zantac Litigation
Express News | GSK Issues Statement Regarding The Zantac (Ranitidine) Litigation; Has Reached A Confidential Settlement With Martin Gross; GSK Does Not Admit Any Liability In This Settlement
GSK: Case Is Related to Ranitidine Litigation
GSK Will Continue to Vigorously Defend Itself, Manage Litigation in Best Interests of Group, Shareholders
Statement: Zantac (Ranitidine) Litigation – Gross Case
American Cancer Society Projects Over 2 Million New Cases in 2024: Biotech Innovations Respond
GSK Plc (GSK): Did This Healthcare Stock Show a Strong Performance in Q1?
Merck Stock Is Slipping. A CDC Committee Considers Pneumococcal Vaccines. -- Barrons.com
Daily short sale tracking: Rivian Automotive's short volume increased by 32 million, with a short sale ratio of 15%
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
CDC Updates RSV Shot Recommendation Among the Elderly; Vaccine Makers Mixed Pre-Bell
GSK Shares Slump After CDC Narrows Age Recommendation for RSV Shots
Nvidia's a Smokescreen. This Is What Matters for Markets, Fed, Trump, and Biden.
Another heavy blow, GlaxoSmithKline (GSK.US) fell sharply due to restrictions on RSV vaccine in the United States.
Zhitong Finance APP learned that the stock price of GlaxoSmithKline (GSK.US) plummeted because US health officials recommended restricting the RSV vaccine to older and higher-risk groups, which may reduce the market share of the company's best-selling vaccine. GlaxoSmithKline's share price fell 7.2% in London trading, wiping out most of the gains since the beginning of this year. The stock fell 3.57% on Wednesday in US trading and fell 1.03% pre-market at press time. Previously, GlaxoSmithKline lost to competitor Pfizer (PFE.US) in a contract to supply millions of doses of vaccines to its home country. This restrictive guidance marks.